Abstract
Reports concerning the effects of Cimetidine on parathyroid hormone levels in primary hyperparathyroidism (1–4) and in secondary hyperparathyroidism of renal failure (5–8) are increasing in number, but lead to disagreeing conclusions. These discrepancies are unclear and could be possibly explained by: 1) a variable compliance to treatment, since no measurement of plasma levels of Cimetidine has been made in these reports, 2) differences in specificity of parathyroid hormone immunoassays, since, in a studied group of hemodialysed patients, the lowering effect of Cimetidine on parathyroid hormone levels previously observed using a carboxyterminal antiserum (5), was not confirmed when the same samples were assayed a second time using an aminoterminal antiserum (9). It has also been suggested (8) that Cimetidine could act on the metabolic fate of circulating parathyroid hormone rather than on its secretion, thus explaining differences between results derived from either carboxy or aminoterminal immunoassays.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
J.C. Sherwood, F.W. Ackroyd, M. Garcia. Effect of Cimetidine on circulating parathyroid hormone in primary hyperparathyroidism. Lancet i: 616 (1980).
F.J. Palmer, T.M. Sawyers, S.J. Wierzbinski. Cimetidine and hyperparathyroidism. Lancet i: 692 (1980).
S. Ljunghall, G. Akerstrom, C. Rubberg, L. Wide, H. Johansson. Cimetidine in primary hyperparathyroidism. Lancet ii: 480 (1980).
M.F. Robinson, A.B. Hayles, H. III. Heath. Failure of Cimetidine to affect calcium homeostasis in familial primary hyperparathyroidism (Multiple endocrine neoplasia, Type I). J. Clin. Endocrinol, Metab. 51: 912 (1980).
A.I. Jacob, D.Jr. Lanier, J. Canterbury, J.J. Bourgoignie. Reduction by Cimetidine of serum parathyroid hormone levels in uremic patients. N. Engl. J. Med. 302: 671 (1980).
C.J. Beehler, J.R. Beckner, C. Rosenquist, S.W. Shankel. Parathyroid hormone suppression by Cimetidine in the uremic patients. Ann. Inter. Med. 93: 840 (1980).
J.L. Vanherweghem, N. Bourgeois, M. Fuss. Cimetidine and parathyroid hormone levels. N. Engl. J. Med. 303: 395 (1980).
C.E. Fiore, L.S. Malatino, J.A. Kanis. Effects of Cimetidine on parathyroid hormone metabolism. Lancet i: 501 (1981).
A.I. Jacob, J.F. Bourgoignies. Cimetidine and parathyroid hormone levels. N. Engl. J. Med. 303: 396 (1980).
J.A. Kanis, M. Earnshaw, G. Heynen, J.G.G. Ledingham, D.O. Oliver, G.G. Russell, C.G. Woods, P. Franchimont, S. Gaspar. Changes in histologic and biochemical indexes of bone turnover after bilateral nephrectomy in patients on hemodialysis. Evidence for a possible role of endogenous calcitonin. N. Engl. J. Med. 296: 1073 (1977).
J. Gueris, C. Ferriere. Hétérogénéité de la parathormone plasmatique chez l’homme. Pathol. Biol. 23: 821 (1975).
C. Desplan, A. Jullienne, M.S. Moukhtar, G. Milhaud. Sensitive assay for biologically active fragment of human parathyroid hormone. Lancet ii: 198 (1977).
J.L. Sebert, A. Fournier, J. Gueris, G. Lambrey, J.F. de Fremont, P. Marie, R. Makdassi, A. Smadja, A. Marie, D. Kuntz, A. Ryckewaert, J. Quichaud, P.J. Meunier. Limit by hyperphosphatemia of the usefulness of vitamin D metabolites (1 — hydroxycholecalciferol and 25 hydroxycholecalciferol) in the treatment of renal osteodystrophy. Metab. Bone. Dis. and Rel. Res. 2: 217 (1980).
P.L. Vigo, E.E. Polli, G. Milhaud, M.S. Moukhtar, C. Desplan, J. Duriez. Aminoterminal parathyroid hormone radioimmunoassay to evaluate bone status in renal failure. Lancet i: 443 (1981).
M.S. Moukhtar, A. Jullienne, P. Rivaille, G. Milhaud. Dosage radioimmunologique de la calcitonine humaine. Etude immunochimique et comparaison avec le dosage biologique. In: Radioimmunoassay and related procedures in clinical medicine and research p. 381, International Atomic Energy Agency, Vienna (1973).
A.M. Parfitt. Correction of plasma calcium measurements. Br. Med. J. 1: 520 (1974).
W.C. Randolph, V.L. Osborne, S.S. Walkenstein, A.P. Intoccia. High-pressure liquid chromatographic analysis of Cimetidine, a histamine H2 — receptor antagonist in blood and urine. J. Pharm. Sci: 66: 1148 (1977).
R. Larsson, G. Bodemar, B. Norlander. Oral absorption of Cimetidine and its clearance in patients with renal failure. Eur. J. Clin. Pharmacol. 15: 153 (1979).
J.J. Schentag, F.B. Cerra, G. Calleri, E. Deglopper, J.Q. Rose, H. Bernhard. Pharmacokinetic and clinical studies in patients with Cimetidine associated mental confusion. Lancet i: 177 (1979).
C.C. Doherty, F.A. O’Connor, M.G. Mc Geown. Cimetidine for duodenal ulceration in patients undergoing hemodialysis. Br. Med. J. 2: 1506 (1977).
R.S. Longley, G.K. Hargis, E.N. Bowser, S.C. Kukreja, P.A. Johnson, B.L. Jackson, W.J. Kawahara, G.A. Williams. Parathyroid hormone and calcitonin secretion: role of histamine H2 receptors. Clin. Res. 28: 398 A (1980).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1982 Plenum Press, New York
About this chapter
Cite this chapter
Sebert, J.L. et al. (1982). Effects of Oral Cimetidine on Parathyroid Hormone and Calcitonin Plasma Levels in Uremic Patients. In: Massry, S.G., Letteri, J.M., Ritz, E. (eds) Regulation of Phosphate and Mineral Metabolism. Advances in Experimental Medicine and Biology, vol 151. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-4259-5_69
Download citation
DOI: https://doi.org/10.1007/978-1-4684-4259-5_69
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-4261-8
Online ISBN: 978-1-4684-4259-5
eBook Packages: Springer Book Archive